Pilot study explores L-carnitine in overweight dogs

Version 2

A newly published pilot study is putting L-carnitine back into the conversation around canine weight management, though with plenty of caveats. In Veterinary Sciences, researchers reported that 30 days of oral L-carnitine supplementation in overweight Golden Retrievers was associated with dose-related changes in selected metabolic markers, reduced body condition score, and lower food intake during a short-term feeding test, but not with measurable weight loss. The paper was published October 6, 2026, and the authors explicitly position it as preliminary work to guide a future controlled trial. (mdpi.com)

That framing matters because interest in adjunctive tools for canine overweight is high, while evidence remains uneven. AAHA’s nutrition and weight management guidance and WSAVA’s nutrition resources continue to emphasize that effective weight reduction depends on a full nutritional assessment, calorie control, diet choice, exercise, and ongoing monitoring. Those guidelines also reflect a broader reality in practice: obesity is common, multifactorial, and often hard for veterinary teams and pet parents to manage consistently over time. (aaha.org)

In the new study, 21 Golden Retrievers ages 8 to 10 were divided into three groups of seven: a control group with body condition score below 7 that received no supplementation, and two overweight groups with body condition score 7 or higher that received 1 g/day or 2 g/day of oral levocarnitine for 30 days. Investigators assessed digestibility, stool quality, body weight, body condition score, appetite, and a range of serum biochemical, endocrinological, and oxidative-status parameters. According to the article summary, the higher-dose group showed reduced food consumption during the appetite test, and both supplemented groups showed metabolic changes that the authors describe as dose-related. (mdpi.com)

Still, the details argue for caution. The paper states there was no measurable body weight loss within the 30-day period, and it flags mixed lipid findings at the 2 g/day dose: lower cholesterol occurred alongside lower HDL and higher triglycerides. The authors also note that the trial was uncontrolled and designed to generate effect-size and dose-selection data for a later randomized, placebo-controlled study. In other words, the study raises a question more than it answers one. (mdpi.com)

The broader literature helps explain why this topic keeps resurfacing. Earlier work has suggested overweight dogs may show altered carnitine-related metabolism, including lower carnitine concentrations in some overweight Labrador Retrievers and signs consistent with reduced fatty acid oxidation or metabolic inflexibility. At the same time, a long-standing review of canine and feline obesity noted that clear, peer-reviewed evidence for a specific clinical benefit of L-carnitine supplementation in dogs has been limited. That makes the new paper notable, but also very much part of an unfinished evidence base rather than a settled one. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical takeaway is that L-carnitine may be worth watching as a possible adjunct, especially in dogs with overweight-related metabolic concerns, but it doesn’t displace established weight-management care. The study’s small sample, single-breed population, short duration, and lack of randomization or placebo control make it difficult to separate supplement effects from baseline differences, feeding behavior, or regression to the mean. In practice, this fits best as a conversation starter with interested pet parents, not as evidence to broadly recommend supplementation for weight loss. Structured monitoring of BCS, MCS, caloric intake, treats, supplements, and follow-up remains the standard. (mdpi.com)

No outside expert commentary or industry response tied specifically to this paper was readily available at the time of writing, which isn’t unusual for an early pilot study. But the lack of immediate reaction may reinforce the paper’s current status: interesting, clinically relevant, and still preliminary. (mdpi.com)

What to watch: The next meaningful step will be whether the authors, or other groups, launch the randomized, placebo-controlled trial they say this study was meant to inform, ideally with a larger and more diverse canine population, longer follow-up, and endpoints that include body composition, metabolic markers, adherence, and clinical outcomes relevant to everyday practice. (mdpi.com)